

# Douglas Sipp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5257419/publications.pdf>

Version: 2024-02-01

74  
papers

2,228  
citations

279798

23  
h-index

233421

45  
g-index

90  
all docs

90  
docs citations

90  
times ranked

2371  
citing authors

#	ARTICLE	IF	CITATIONS
1	ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. <i>Stem Cell Reports</i> , 2021, 16, 1398-1408.	4.8	134
2	New trends in cellular therapy. <i>Development (Cambridge)</i> , 2020, 147, .	2.5	24
3	Downgrading of regulation in regenerative medicine. <i>Science</i> , 2019, 365, 644-646.	12.6	23
4	Stem Cell Businesses and Right to Try Laws. <i>Cell Stem Cell</i> , 2019, 25, 304-305.	11.1	5
5	Stem cell mismarketing: Implications for the transfusion community. <i>ISBT Science Series</i> , 2019, 14, 45-48.	1.1	5
6	The politics of evidence in online illness narratives: An analysis of crowdfunding for purported stem cell treatments. <i>Health (United Kingdom)</i> , 2019, 23, 436-457.	1.5	16
7	No Vacillation on HPV Vaccination. <i>Cell</i> , 2018, 172, 1163-1167.	28.9	20
8	Japan Strengthens Regenerative Medicine Oversight. <i>Cell Stem Cell</i> , 2018, 22, 153-156.	11.1	20
9	Rejuvenating Regenerative Medicine Regulation. <i>New England Journal of Medicine</i> , 2018, 378, 504-505.	27.0	24
10	Clear up this stem-cell mess. <i>Nature</i> , 2018, 561, 455-457.	27.8	217
11	Challenges in the Regulation of Autologous Stem Cell Interventions in the United States. <i>Perspectives in Biology and Medicine</i> , 2018, 61, 25-41.	0.5	17
12	Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions. <i>Npj Regenerative Medicine</i> , 2018, 3, 5.	5.2	31
13	Cell Churches and Stem Cell Marketing in South Korea and the United States. <i>Developing World Bioethics</i> , 2017, 17, 167-172.	0.9	2
14	Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations. <i>Journal of Bioethical Inquiry</i> , 2017, 14, 261-273.	1.5	25
15	Marketing of unproven stem cell-based interventions: A call to action. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	147
16	Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 177-179.	4.7	5
17	A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicine. <i>Npj Regenerative Medicine</i> , 2017, 2, 21.	5.2	5
18	Identity and ownership issues in the regulation of autologous cells. <i>Regenerative Medicine</i> , 2017, 12, 827-838.	1.7	11

#	ARTICLE	IF	CITATIONS
19	The malignant niche: safe spaces for toxic stem cell marketing. <i>Npj Regenerative Medicine</i> , 2017, 2, 33.	5.2	11
20	Show drugs work before selling them. <i>Nature</i> , 2017, 543, 174-175.	27.8	10
21	Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product. <i>Cell Stem Cell</i> , 2016, 18, 436-437.	11.1	16
22	Confronting stem cell hype. <i>Science</i> , 2016, 352, 776-777.	12.6	109
23	New ISSCR guidelines: clinical translation of stem cell research. <i>Lancet</i> , The, 2016, 387, 1979-1981.	13.7	42
24	Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. <i>Stem Cell Reports</i> , 2016, 6, 787-797.	4.8	172
25	Global Distribution of Businesses Marketing Stem Cell-Based Interventions. <i>Cell Stem Cell</i> , 2016, 19, 158-162.	11.1	126
26	Bioethics in China: No wild east. <i>Nature</i> , 2016, 534, 465-467.	27.8	7
27	Policy: Global standards for stem-cell research. <i>Nature</i> , 2016, 533, 311-313.	27.8	41
28	Paolo Bianco (1955-2015). <i>Cell Stem Cell</i> , 2015, 17, 649-650.	11.1	2
29	Enabling Consistency in Pluripotent Stem Cell-Derived Products for Research and Development and Clinical Applications Through Material Standards. <i>Stem Cells Translational Medicine</i> , 2015, 4, 217-223.	3.3	30
30	Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCB). <i>Regenerative Medicine</i> , 2015, 10, 1-44.	1.7	100
31	Conditional Approval: Japan Lowers the Bar for Regenerative Medicine Products. <i>Cell Stem Cell</i> , 2015, 16, 353-356.	11.1	54
32	Regulation: Sell help not hope. <i>Nature</i> , 2014, 510, 336-337.	27.8	63
33	Global Bionetworks and Challenges in Regulating Autologous Adult Stem Cells. <i>American Journal of Medicine</i> , 2013, 126, 941-943.	1.5	4
34	Tissue Interactions in Neural Crest Cell Development and Disease. <i>Science</i> , 2013, 341, 860-863.	12.6	120
35	The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation. <i>Stem Cells and Development</i> , 2013, 22, 63-72.	2.1	7
36	Oversight for Clinical Uses of Autologous Adult Stem Cells: Lessons from International Regulations. <i>Cell Stem Cell</i> , 2013, 13, 647-651.	11.1	28

#	ARTICLE	IF	CITATIONS
37	How to hasten open access. <i>Nature</i> , 2013, 495, 442-443.	27.8	3
38	Direct-to-Consumer Stem Cell Marketing and Regulatory Responses. <i>Stem Cells Translational Medicine</i> , 2013, 2, 638-640.	3.3	25
39	Pay-to-participate funding schemes in human cell and tissue clinical studies. <i>Regenerative Medicine</i> , 2012, 7, 105-111.	1.7	31
40	Stem Cell Science On the Rise in China. <i>Cell Stem Cell</i> , 2012, 10, 12-15.	11.1	22
41	U.S. Regulation of Stem Cells as Medical Products. <i>Science</i> , 2012, 338, 1296-1297.	12.6	51
42	Disclosure and management of research findings in stem cell research and banking: policy statement. <i>Regenerative Medicine</i> , 2012, 7, 439-448.	1.7	31
43	Converging Ideological Currents in the Adult Stem Cell Marketing Phenomenon. <i>Ethics in Biology, Engineering &amp; Medicine</i> , 2012, 3, 275-286.	0.1	3
44	Stem cell stratagems in alternative medicine. <i>Regenerative Medicine</i> , 2011, 6, 407-414.	1.7	18
45	Global Challenges in Stem Cell Research and the Many Roads Ahead. <i>Neuron</i> , 2011, 70, 573-576.	8.1	7
46	The unregulated commercialization of stem cell treatments: a global perspective. <i>Frontiers of Medicine</i> , 2011, 5, 348-355.	3.4	50
47	Publishing SNP Genotypes of Human Embryonic Stem Cell Lines: Policy Statement of the International Stem Cell Forum Ethics Working Party. <i>Stem Cell Reviews and Reports</i> , 2011, 7, 482-484.	5.6	14
48	2010 International Forum on Stem Cells (November 11-13; Tianjin, China). <i>Stem Cell Reviews and Reports</i> , 2011, 7, 479-481.	5.6	1
49	New IJH guidelines highlight greater transparency. <i>International Journal of Hematology</i> , 2011, 93, 411-412.	1.6	0
50	Global update: Japan. <i>Regenerative Medicine</i> , 2011, 6, 160-162.	1.7	1
51	Ethical Aspects of Stem Cell-Based Clinical Translation: Research, Innovation, and Delivering Unproven Interventions. <i>Pancreatic Islet Biology</i> , 2011, , 125-135.	0.3	1
52	Hope Alone Is Not an Outcome: Why Regulations Makes Sense for the Global Stem Cell Industry. <i>American Journal of Bioethics</i> , 2010, 10, 33-34.	0.9	11
53	Regulatory Impacts on Stem Cell Research in Japan. <i>Cell Stem Cell</i> , 2010, 6, 415-418.	11.1	21
54	Patients Beware: Commercialized Stem Cell Treatments on the Web. <i>Cell Stem Cell</i> , 2010, 7, 43-49.	11.1	50

#	ARTICLE	IF	CITATIONS
55	Challenges in the clinical application of induced pluripotent stem cells. <i>Stem Cell Research and Therapy</i> , 2010, 1, 9.	5.5	9
56	The rocky road to regulation. <i>Nature Reports Stem Cells</i> , 2009, , .	0.0	8
57	Monitoring and Regulating Offshore Stem Cell Clinics. <i>Science</i> , 2009, 323, 1564-1565.	12.6	93
58	Stem cells and regenerative medicine on the Asian horizon: an economic, industry and social perspective. <i>Regenerative Medicine</i> , 2009, 4, 911-918.	1.7	10
59	Stem cell research in Asia: A critical view. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 853-856.	2.6	10
60	Issues in stem cells in Asia and SNAP decisions. <i>International Journal of Hematology</i> , 2009, 90, 278-279.	1.6	1
61	Gold Standards in the Diamond Age: The Commodification of Pluripotency. <i>Cell Stem Cell</i> , 2009, 5, 360-363.	11.1	10
62	Millennium ends Takeda's US shopping spree. <i>Nature Biotechnology</i> , 2008, 26, 593-595.	17.5	0
63	GSK moves on Sirtris. <i>Nature Biotechnology</i> , 2008, 26, 595-595.	17.5	3
64	No Borders, Only Frontiers: The Global Stem Cell Research Community and theÂISSCR. <i>Cell Stem Cell</i> , 2007, 1, 53-54.	11.1	2
65	Asian-Pacific researchers and officials form stem-cell network. <i>Nature Reports Stem Cells</i> , 2007, , .	0.0	1
66	Asian-Pacific stem cell scientists discuss regional network. <i>Nature Reports Stem Cells</i> , 2007, , .	0.0	0
67	Dualities of Christ and stem cells. <i>Nature Reports Stem Cells</i> , 2007, , .	0.0	1
68	Japan-China merger puts growth in East Asia first. <i>Nature Biotechnology</i> , 2005, 23, 907-907.	17.5	0
69	Japanese giants renew interest in industrial biotech. <i>Nature Biotechnology</i> , 2005, 23, 275-276.	17.5	2
70	Japanese firms broaden investment focus to early biotech. <i>Nature Biotechnology</i> , 2004, 22, 931-932.	17.5	3
71	'Fast-track' drug approvals hit speed bumps in Japan. <i>Nature Medicine</i> , 2004, 10, 883-883.	30.7	3
72	Reports of SIDS-virus link greatly exaggerated, experts say. <i>Nature Medicine</i> , 2004, 10, 1147-1147.	30.7	0

#	ARTICLE	IF	CITATIONS
73	Discovery and characterization of the cadherin family of cell adhesion molecules. An interview with Masatoshi Takeichi.. International Journal of Developmental Biology, 2004, 48, 387-396.	0.6	5
74	Offshore stem cell treatments. Nature Reports Stem Cells, 0, , .	0.0	19